SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Immunomedics (IMMU) - moderated
An SI Board Since September 2006
Posts SubjectMarks Bans Symbol
63365 356 15 IMMU
Emcee:  idahoranch1 Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
63136Thanks for the corrections, GG. I also fully agree with your characterization oOlecranon-6/13/2025
63135So the common denominator here is not Elevidys, but the vector itself, which makghettogoulash16/12/2025
63134SRPT: A couple of corrections. Elevidys already has Full Approval in ambulatory ghettogoulash16/12/2025
63133Perhaps I was a little too glib in my first statement regarding SRPT risks. JusOlecranon16/11/2025
63132I’m going push back on that a little; the worst is just beginning.dorightbythem16/11/2025
63131That is certainly the hope. I have been increasing holdings in this range for aluckydog88-6/10/2025
63130IMHO RFKJr’s worst is already priced in.Olecranon16/10/2025
63129well i guess the risk is RFK and the uncertainty he brings. this is what happenluckydog8816/9/2025
63128IMHO, it’s rare to see a stock a stock like Sarepta with so much near/medium terOlecranon-6/9/2025
63127came across this today: 03:01 PM EDT, 06/09/2025 (MT Newswires) -- Sarepta Therluckydog8826/9/2025
63126Scotiabank Upgrades Sarepta Therapeutics to Sector Outperform From Sector Perforluckydog8826/6/2025
63125re: SRPT undervalued Right, but every damn time there's a buying opportuniterickerickson16/5/2025
63124I heard that new guy at FDA that spooked everyone (Prasad) about SRPT was intervstockdoc7795/28/2025
63123Trodelvy® Demonstrates Highly Statistically Significant & Clinically MeOlecranon105/23/2025
63122Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatluckydog8835/21/2025
63121Thanks again for all that, allatwwk. I’m surprised that UNH medicare fraud was Olecranon-5/19/2025
63120I enjoyed the conference a lot. Panel after panel, really good questions from aallatwwk15/17/2025
63119Thanks, allatwwk. Were you happy with the quality of the information presented?Olecranon-5/17/2025
63118Sarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAluckydog8825/16/2025
63117Companies ranked high on innovation and invention at the STAT conference. The prallatwwk25/15/2025
63116Approval by Japan is a huge vote of confidence in elevydis. The Japanese are nostockdoc77105/14/2025
63115ctmx acquired price abbv imgn approved product 1 indicationforgetme-5/13/2025
63114for those following srpt: Sarepta Therapeutics Announces Approval in Japan of ELluckydog8835/13/2025
63113ctmx abbv met adc data medium 3rd line pts were not as sick Efficacy: ORR: 18% forgetme15/12/2025
63112ctmx great data and wider application than immu trop adcforgetme-5/12/2025
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News